Scalper1 News
The drug industry’s recent spate of deals got another shot in the arm Monday as Bristol-Myers Squibb announced plans to acquire a privately held drugmaker for up to $1.25 billion, a day after Valeant Pharmaceuticals International (VRX) said that it will buy Salix Pharmaceuticals for $14.5 billion. Bristol-Myers Squibb (BMY) early Monday agreed to buy Flexus Biosciences, a San Carlos, Calif.-based biotech, to expand its line of anti-cancer Scalper1 News
Scalper1 News